Ci T, Zhang W, Qiao Y, Li H, Zang J, Li H, et al. Delivery strategies in treatments of leukemia. Chem Soc Rev. 2022;51:2121–44.

Article  CAS  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Cunha Junior AD, Bragagnoli AC, Costa FO, Carvalheira JBC. Repurposing metformin for the treatment of gastrointestinal cancer. World J Gastroenterol. 2021;27:1883–904.

Article  PubMed  PubMed Central  Google Scholar 

Bartman CR, Weilandt DR, Shen Y, Lee WD, Han Y, TeSlaa T, et al. Slow TCA flux and ATP production in primary solid tumours but not metastases. Nature. 2023;614:349–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johar D, Elmehrath AO, Khalil RM, Elberry MH, Zaky S, Shalabi SA, et al. Protein networks linking Warburg and reverse Warburg effects to cancer cell metabolism. BioFactors. 2021;47:713–28.

Article  CAS  PubMed  Google Scholar 

Alden RS, Kamran MZ, Bashjawish BA, Simone BA. Glutamine metabolism and radiosensitivity: beyond the Warburg effect. Front Oncol. 2022;12:1070514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21:141–62. This review reveals the research progress of targeted metabolism in tumors.

Article  CAS  PubMed  Google Scholar 

•• de Oliveira S, Houseright RA, Graves AL, Golenberg N, Korte BG, Miskolci V, et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J Hepatol. 2019;70:710–21. This paper comprehensively summarizes and explains the literature of metformin in the treatment of tumor, highlighting the main controversial issues and their clinical significance.

Article  PubMed  Google Scholar 

Najafi F, Rajati F, Sarokhani D, Bavandpour M, Moradinazar M. The Relationship between metformin consumption and cancer risk: an updated umbrella review of systematic reviews and meta-analyses. Int J Prev Med. 2023;14:90.

PubMed  PubMed Central  Google Scholar 

Tseng CH. Metformin use and leukemia risk in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2020;11:541090.

Article  PubMed  Google Scholar 

Ma T, Tian X, Zhang B, Li M, Wang Y, Yang C, et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature. 2022;603:159–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15:569–89.

Article  CAS  PubMed  Google Scholar 

Zhang CS, Jiang B, Li M, Zhu M, Peng Y, Zhang YL, et al. The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. Cell Metab. 2014;20:526–40.

Article  CAS  PubMed  Google Scholar 

Zhang T, Xu D, Trefts E, Lv M, Inuzuka H, Song G, et al. Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. Science. 2023;380:1372–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daugan M, Dufay Wojcicki A, d’Hayer B, Boudy V. Metformin: an anti-diabetic drug to fight cancer. Pharmacol Res. 2016;113:675–85.

Article  CAS  PubMed  Google Scholar 

Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021;101:1371–426.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Das A, Reis F. mTOR signaling: new insights into cancer, cardiovascular diseases, diabetes and aging. Int J Mol Sci. 2023;24:13628.

Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35.

Article  CAS  PubMed  Google Scholar 

Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005;437:1109–11.

Article  CAS  PubMed  Google Scholar 

Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood. 2010;116:4262–73.

Article  CAS  PubMed  Google Scholar 

Gayatri MB, Kancha RK, Behera A, Patchva D, Velugonda N, Gundeti S, et al. AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects. Cell Death Discov. 2023;9:401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng Z, Bian Y, Zhang Y, Ren G, Li G. Metformin activates AMPK/SIRT1/NF-kappaB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis. Cell Cycle. 2020;19:1089–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou Y, Cai S, Yu S, Lin H. Metformin induces ferroptosis by targeting miR-324-3p/GPX4 axis in breast cancer. Acta Biochim Biophys Sin (Shanghai). 2021;53:333–41.

Article  CAS  PubMed  Google Scholar 

Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13:113.

Article  PubMed  PubMed Central  Google Scholar 

Li H, Liu L, Chen HY, Yan X, Li RL, Lan J, et al. Mogrol suppresses lung cancer cell growth by activating AMPK-dependent autophagic death and inducing p53-dependent cell cycle arrest and apoptosis. Toxicol Appl Pharmacol. 2022;444: 116037.

Article  CAS  PubMed  Google Scholar 

Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol. 2000;10:1247–55.

Article  CAS  PubMed  Google Scholar 

Chen Q, Zhang H, Yang Y, Zhang S, Wang J, Zhang D, Yu H. Metformin attenuates UVA-induced skin photoaging by suppressing mitophagy and the PI3K/AKT/mTOR pathway. Int J Mol Sci. 2022;23(13):6960.

Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11:390–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raafat SN, El Wahed SA, Badawi NM, Saber MM, Abdollah MRA. Enhancing the anticancer potential of metformin: fabrication of efficient nanospanlastics, in vitro cytotoxic studies on HEP-2 cells and reactome enhanced pathway analysis. Int J Pharm X. 2023;6: 100215.

CAS  PubMed  PubMed Central  Google Scholar 

Jang SK, Hong SE, Lee DH, Kim JY, Kim JY, Ye SK, et al. Inhibition of mTORC1 through ATF4-induced REDD1 and Sestrin2 expression by metformin. BMC Cancer. 2021;21:803.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marini C, Salani B, Massollo M, Amaro A, Esposito AI, Orengo AM, et al. Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle. 2013;12:3490–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen YC, Li H, Wang J. Mechanisms of metformin inhibiting cancer invasion and migration. Am J Transl Res. 2020;12:4885–901.

CAS  PubMed  PubMed Central  Google Scholar 

Salani B, Marini C, Rio AD, Ravera S, Massollo M, Orengo AM, et al. Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. Sci Rep. 2013;3:2070.

Article  PubMed  PubMed Central  Google Scholar 

Wu D, Hu D, Chen H, Shi G, Fetahu IS, Wu F, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature. 2018;559:637–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou X, Chen J, Yi G, Deng M, Liu H, Liang M, et al. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget. 2016;7:873–84.

Article  PubMed  Google Scholar 

Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 2018;78:1779–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim Y, Vagia E, Viveiros P, Kang CY, Lee JY, Gim G, et al. Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC). Cancer Immunol Immunother. 2021;70:961–5.

Article  CAS